Keywords: thalomid, effective, prostate, cancer, biopharmaceutical, firm, celgene

Thalomid effective in prostate cancer

Article | 12 July 2004

Print This

US biopharmaceutical firm Celgene has announced the results of arandomized Phase II trial conducted by the National Cancer Institute which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in